1 Introduction
1.1 What Is This Report About?
1.2 Metabolic Disorders Market Segmentation
1.3 Definitions of Markets Covered in the Report
2 Metabolic Disorders Market, United States
2.1 Metabolic Disorders Market, United States, Revenue ($m), 2024-2036
2.1.1 Cholesterol Tests Market, United States, Revenue ($m), by Segment, 2024-2036
2.1.2 Diabetes Assays Market, United States, Revenue ($m), by Segment, 2024-2036
2.2 Metabolic Disorders Market, United States, Volume (Units), 2024-2036
2.2.1 Cholesterol Tests Market, United States, Volume (Units), by Segment, 2024-2036
2.2.2 Diabetes Assays Market, United States, Volume (Units), by Segment, 2024-2036
2.3 Metabolic Disorders Market, United States, Average Price ($), 2024-2036
2.4 Metabolic Disorders Market, United States, Company Share by Revenue ($m), 2025
3 Metabolic Disorders Market Pipeline Products
3.1 Metabolic Disorders Market Pipeline Products
3.2 Metabolic Disorders - Pipeline Products by Stage of Development
3.3 Metabolic Disorders - Pipeline Products by Segment
3.4 Metabolic Disorders - Pipeline Products by Territory
3.5 Metabolic Disorders - Pipeline Products by Regulatory Path
3.6 Metabolic Disorders - Pipeline Products by Estimated Approval Date
4 Overview of Key Companies in United States, Metabolic Disorders Market
4.1 Abbott Laboratories
4.1.1 Company Overview
4.2 Siemens Healthineers AG
4.2.1 Company Overview
4.3 Roche Diagnostics International Ltd
4.3.1 Company Overview
4.4 Ortho Clinical Diagnostics Holdings Ltd (Inactive)
4.4.1 Company Overview
4.5 Beckman Coulter Inc
4.5.1 Company Overview
5 Recent Developments
5.1 Corporate Communications
5.1.1 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
5.1.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
5.1.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
5.1.4 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager
5.1.5 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
5.1.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.2 Other Significant Developments
5.2.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
5.2.2 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
5.2.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
5.2.4 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.3 Product News
5.3.1 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics
5.3.2 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV
5.3.3 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
5.3.4 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
5.3.5 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.3.6 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
5.3.7 Jun 23, 2025: New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease
5.4 Research And Development
5.4.1 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
5.5 Strategy And Business Planning
5.5.1 Apr 14, 2026: Vida Health and OURA to Deliver Continuous, Personalized Metabolic Care
5.5.2 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics
5.5.3 Nov 11, 2025: Expanse Medical Expands to Providence, Rhode Island
5.5.4 Nov 10, 2025: Synthego Introduces High-Performance Molecular Reagents for Diagnostics
5.5.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
5.5.6 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics
5.5.7 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics
6 Appendix
6.1 Research Methodology
6.1.1 Coverage
6.1.2 Secondary Research
6.1.3 Primary Research
6.1.4 Market Modeling and Forecasting
6.1.5 Company Share Analysis
6.1.6 Benchmarking
6.2 the Analyst Consulting
6.3 Contact Us
6.4 Disclaimer
List of Tables
Table 1: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 2: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 3: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 4: Metabolic Disorders Market, United States, Volume (Units), 2024-2036
Table 5: Cholesterol Tests Market, United States, Volume (Units), 2024-2036
Table 6: Diabetes Assays Market, United States, Volume (Units), 2024-2036
Table 7: Metabolic Disorders Market, United States, Average Price ($), 2024-2036
Table 8: Metabolic Disorders Market, United States, Company Share by Revenue ($m), USD Constant, 2025
Table 9: Metabolic Disorders Market Pipeline Products
Table 10: Metabolic Disorders - Pipeline Products by Stage of Development
Table 11: Metabolic Disorders Companies - Pipeline Products by Stage of Development
Table 12: Metabolic Disorders - Pipeline Products by Segment
Table 13: Metabolic Disorders - Pipeline Products by Territory
Table 14: Metabolic Disorders - Pipeline Products by Regulatory Path
Table 15: Metabolic Disorders - Pipeline Products by Estimated Approval Date
Table 16: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
List of Figures
Figure 1: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 2: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 3: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 4: Metabolic Disorders Market, United States, Volume (Units), 2024-2036
Figure 5: Cholesterol Tests Market, United States, Volume (Units), 2024-2036
Figure 6: Diabetes Assays Market, United States, Volume (Units), 2024-2036
Figure 7: Metabolic Disorders Market, United States, Company Share (%), 2025
Figure 8: Metabolic Disorders - Pipeline Products by Stage of Development
Figure 9: Metabolic Disorders - Pipeline Products by Segment
Figure 10: Metabolic Disorders - Pipeline Products by Territory
Figure 11: Metabolic Disorders - Pipeline Products by Regulatory Path
Figure 12: Metabolic Disorders - Pipeline Products by Estimated Approval Date
